(Q40545176)

21 September 2017

Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3. (English)

1 reference

21 September 2017

Mahy P

1

1 reference

21 September 2017

De Bast M

2

1 reference

21 September 2017

Leveque PH

3

1 reference

21 September 2017

Gillart J

4

1 reference

21 September 2017

Labar D

5

1 reference

21 September 2017

Marchand J

6

1 reference

21 September 2017

Gregoire V

7

1 reference

21 September 2017

10 June 2004

1 reference

21 September 2017

10

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

21 September 2017

31

1 reference

21 September 2017

9

1 reference

21 September 2017

1263-1272

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-004-1573-2

21 September 2017

0 references

cites work

In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors

1 reference

12 December 2020

Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays

1 reference

12 December 2020

2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.

1 reference

12 December 2020

Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia

1 reference

12 December 2020

Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.

1 reference

12 December 2020

Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole

1 reference

12 December 2020

In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium

1 reference

12 December 2020

Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.

1 reference

12 December 2020

Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells

1 reference

12 December 2020

Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio

1 reference

12 December 2020

Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography

1 reference

12 December 2020

Techniques to assess the oxygenation of human tumors. State of the art

1 reference

12 December 2020

Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients

1 reference

12 December 2020

Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia

1 reference

12 December 2020

Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole.

1 reference

12 December 2020

Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT

1 reference

12 December 2020

Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies.

1 reference

12 December 2020

Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.

1 reference

12 December 2020

Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.

1 reference

12 December 2020

Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5

1 reference

12 December 2020

Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes.

1 reference

12 December 2020

Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET.

1 reference

12 December 2020

Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole

1 reference

12 December 2020

Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole

1 reference

12 December 2020

Distribution of pimonidazole and RSU 1069 in tumour and normal tissues

1 reference

12 December 2020

Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1.

1 reference

12 December 2020

Retention of misonidazole in normal and malignant tissues: interplay of hypoxia and reductases

1 reference

12 December 2020

Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.

1 reference

12 December 2020

Pharmacokinetics of [18F]FETNIM: a potential marker for PET.

1 reference

12 December 2020

Concepts of oxygen transport at the microcirculatory level.

1 reference

12 December 2020

Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules

1 reference

12 December 2020

Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays

1 reference

12 December 2020

Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole.

1 reference

12 December 2020

Imaging hypoxia in tumors

1 reference

12 December 2020

Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia

1 reference

12 December 2020

Time-dose relationships in the mouse esophagus

1 reference

12 December 2020

Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouse

1 reference

12 December 2020

Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma

1 reference

12 December 2020

Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].

1 reference

12 December 2020

Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5.

1 reference

12 December 2020

Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia

1 reference

12 December 2020

Labeled metronidazoles as potential new agents for amebic hepatic abscess imaging

1 reference

12 December 2020

Synthesis of [18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia

1 reference

12 December 2020

10.1007/S00259-004-1573-2

Identifiers

DOI

1 reference

21 September 2017

1 reference